Brexu-cel Clinical Report | Hackensack Meridian Health   

John Theurer Cancer Center at Hackensack University Medical Center Research Helps Establish Durable Responses After KTE-X19

ZUMA-2 study long-range follow-up in relapsed/refractory mantle cell lymphoma (R/R MCL)

Brexucabtagene Autoleucel

John Theurer Cancer Center at Hackensack University Medical Center researchers helped identify factors associated with long-term response to KTE-X19 (brexu-cel), evaluated patient and product characteristics by response status at 24 mo post infusion in ZUMA-2. Results were published in Blood. Here are a few notable findings:

  • After ~3-years median follow-up, brexu-cel continues to demonstrate durable responses with 49% of patients in ongoing response at 24 months post infusion.
  • Ongoing responders had lower ECOG scores and tumor burden, as well as less frequent use of bridging therapy and less intense regimens for previous relapses.
  • Study suggests the potential for greater benefit with brexu-cel if given in earlier course of disease.

A modest increase in the median total number of infused CCR7+ cells was observed in ongoing vs. relapsed responders suggesting continuous memory T-Cell differentiation could potentially have a role in achieving durable responses.

Learn more about innovations in cancer treatments at Hackensack University Medical Center.

Best Regional Hospitals
We use cookies to improve your experience. Please read our Privacy Policy or click Accept.